Do analysts agree on Trillium Therapeutics (TRIL) stock's price target?
Trillium Therapeutics (NASDAQ:TRIL) Price Target and Consensus Rating 7 Wall Street analysts have issued ratings and price targets for Trillium Therapeutics in the last 12 months. Their average twelve-month price target is $21.83, predicting that the stock has a possible upside of 148.67%.
What is the price targets for TRIL Inc (TRIL)?
The high price target for TRIL is $4.00 and the low price target for TRIL is $4.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
What is the upside from Trillium Therapeutics (TRX) stock?
According to analysts, Trillium Therapeutics's stock has a predicted upside of 35.65% based on their 12-month price targets. What analysts cover Trillium Therapeutics?
What does it mean when analysts hold TRIL on hold?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRIL, but not buy additional shares or sell existing shares. View analyst ratings for Trillium Therapeutics or view top-rated stocks. What price target have analysts set for TRIL?
Is tril stock a good buy?
(NASDAQ:TRIL) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for TRIL is 67.5. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score.
Will tril stock go up?
Trillium Therapeutics Inc quote is equal to 18.440 USD at 2022-07-11. Based on our forecasts, a long-term increase is expected, the "TRIL" stock price prognosis for 2026-11-16 is 51.043 USD. With a 5-year investment, the revenue is expected to be around +176.8%.
What will happen to Trillium Therapeutics stock?
In connection with the acquisition, Trillium's common shares will be delisted from the Nasdaq Capital Market. Trillium's common shares will be delisted from the Toronto Stock Exchange on or before November 19, 2021.
What is the target price for Lucid stock?
Stock Price TargetsHigh$43.00Median$33.00Low$12.00Average$30.25Current Price$18.24
Who did Pfizer buy out?
“We are excited to announce Pfizer's proposed acquisition of Biohaven, recognizing the market leadership of NURTEC® ODT, our breakthrough all in one migraine therapy, and the untapped potential of our CGRP franchise,” said Vlad Coric, MD, Chairman and Chief Executive Officer of Biohaven.
Did Pfizer buy a new company?
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
What companies has Pfizer bought?
Following the news that the American giant is buying cancer drug company Medivation for $14 billion, here are some of Pfizer's most expensive deals to date:King Pharmaceuticals, $3.6 billion. Pfizer acquired King Pharmaceuticals in 2010. ... Hospira, $15.2 billion. ... Wyeth, $68 billion. ... Warner-Lambert, $90.2.
Is Lucid better than Tesla?
The entry-level Tesla Model S has 375 miles of range, while the best-possible range for a Model S is 405 miles. As for the Lucid Air, the entry-level Lucid Air Pure gets 406 miles of range, while the best possible range for the Lucid Air is a whopping 520 miles.
Is lucid a Buy Sell or Hold?
Lucid Group has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.
Is LCID a Buy Sell or Hold?
The Historical Cash Flow Growth is the longer-term (3-5 year annualized) growth rate of the cash flow change....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Should I sell my trillium stock?
The consensus among Wall Street research analysts is that investors should "hold" Trillium Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRIL, but not buy additional shares or sell existing shares.
Did Pfizer buy Trillium?
Trillium is now a completely owned Pfizer subsidiary and the deal is claimed to boost the latter's oncology portfolio by adding advanced, experimental immuno-therapeutics to treat haematological cancers. With the acquisition, Pfizer gained rights to two lead molecules of Trillium, TTI-622 and TTI-621.
How do I invest in Trillium?
How to buy TrilliumCheck CoinMarketCap to see where you can buy Trillium and with which currencies. For each cryptocurrency, CoinMarketCap provides a list of purchasing options (also known as market pairs). ... Pick a platform to make your purchase. ... Make the purchase on your chosen platform.
What is Trillium Therapeutics's consensus rating and price target?
According to the issued ratings of 5 analysts in the last year, the consensus rating for Trillium Therapeutics stock is Hold based on the current 5...
Do Wall Street analysts like Trillium Therapeutics more than its competitors?
Analysts like Trillium Therapeutics stock less than the stock of other Medical companies. The consensus rating for Trillium Therapeutics is Hold wh...
Do MarketBeat users like Trillium Therapeutics more than its competitors?
MarketBeat users like Trillium Therapeutics stock more than the stock of other Medical companies. 72.94% of MarketBeat users gave Trillium Therapeu...
Does Trillium Therapeutics's stock price have much upside?
According to analysts, Trillium Therapeutics's stock has a predicted upside of 4.88% based on their 12-month price targets.
Should I buy or sell Trillium Therapeutics stock right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 5 hol...
What is Trillium Therapeutics' stock price forecast for 2022?
5 analysts have issued 12 month target prices for Trillium Therapeutics' stock. Their forecasts range from $18.50 to $18.50. On average, they predi...
How were Trillium Therapeutics' earnings last quarter?
Trillium Therapeutics Inc. (NASDAQ:TRIL) issued its quarterly earnings results on Thursday, November, 18th. The biotechnology company reported ($0....
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the following people: Jan Skvarka , President, Chief Executive Officer & Director James T. Parson...
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Maravai LifeSciences (MRVI) , Legend Biotech (LEGN) , Sarepta Therapeutics (SRP...
What other stocks do shareholders of Trillium Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmac...
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."
What is Trillium Therapeutics' stock price today?
One share of TRIL stock can currently be purchased for approximately $18.44.
How much money does Trillium Therapeutics make?
Trillium Therapeutics (NASDAQ:TRIL) has a market capitalization of $1.94 billion and generates $150 thousand in revenue each year. The biotechnolog...
Trillium Therapeutics (TSE:TRIL) Price Target and Consensus Rating
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Price Target Consensus
Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter.
Analyst Ratings By Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Average Share Price and Price Target by Month
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
Trillium Therapeutics (TSE:TRIL) Analyst Ratings Frequently Asked Questions
According to the issued ratings of 1 analysts in the last year, the consensus rating for Trillium Therapeutics stock is Hold based on the current 1 hold rating for TRIL. The average twelve-month price target for Trillium Therapeutics is C$18.50 with a high price target of C$18.50 and a low price target of C$18.50.
What is the ticker symbol for Trillium Therapeutics?
Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."
How much does Trillium Therapeutics make?
How much money does Trillium Therapeutics make? Trillium Therapeutics has a market capitalization of $712.42 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-59,350,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.
What is Trillium Therapeutics?
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.
Does Trillium Therapeutics pay dividends?
Trillium Therapeutics does not currently pay a dividend.
